Trial · NCT02874924

Effect of mTOR Inhibition and Other Metabolism Modulating Interventions on the Elderly

NCT02874924, Phase 2, Completed, The University of Texas Health Science Center at San Antonio; results first posted 2018-12-04

3 sourcestrials-2026-11-12-0.5.0

Download JSON

Cite this record

ConductScience Library. Effect of mTOR Inhibition and Other Metabolism Modulating Interventions on the Elderly. Trials, record NCT02874924. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02874924

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Effect of mTOR Inhibition and Other Metabolism Modulating Interventions on the Elderly
NCT number: NCT02874924
Status: Completed
Phases: Phase 2
Enrollment: 34 participants, actual
Lead sponsor: The University of Texas Health Science Center at San Antonio
Conditions: Aging
Interventions: Rapamycin, Placebo, Rapamycin
First posted: 2016-08-22
Last updated: 2018-12-04
Results first posted: 2018-12-04

Source ClinicalTrials.gov

Registered outcomes5

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Immunological Responses	8 weeks	T cell function measured by number of T cells per millimeter cubed.
Secondary	Physical Performance	8 weeks	walking speed: Timed 40-foot walk: each participant will perform 3 walks (timed with a stopwatch) at their preferred walking speed over a measured 40-foot path. Results will be averaged for analysis. The faster the walking speed the better the performance.
Secondary	Cognitive Function	8 weeks	The Executive Interview (EXIT25) - This test is a brief bedside test that consists of 25 items measuring abilities that include: Executive functioning, Motor sequencing, Spoken alternate sequencing, Verbal fluency, Design fluency, Persistence, Resistance to interference, Reflexes Scoring directions are listed under each of the 25 portions of this test. For each section, the client is given a score of a 0, 1, or 2. A score "0" indicates no impairment, a score of "1" indicates some impairment, and a score of "2" indicates severe impairment. Directions for what qualifies as each score are listed under each section. The points are totaled and criteria are given for severe, moderate, and no impairment. Minimum score is -0- and maximum is 50. A score of 15 or below indicates normal executive functioning, a score of above 15 indicates moderate to severe impairment.
Other	Cardiovascular Effect	8 weeks	Pulse Wave Velocity is measured using an Electrocardiogram (ECG)
Other	Volume of Diastolic Filling	8 weeks	Diastolic function was assessed using Magnetic Resonance Imaging (MRI) of the heart to measure the diastolic filling of the heart in participants in the open label rapamycin group.

Source ClinicalTrials.gov

Outcomes5

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Immunological Responses	8 weeks	In the cardiovascular arm, no T cell function was analyzed.	cells/mm^3	MEAN
SECONDARY	Physical Performance	8 weeks	Walking speed was not analyzed in the cardiovascular group.	Seconds	MEAN
SECONDARY	Cognitive Function	8 weeks	EXIT25 was not collected or analyzed in cardiovascular group.	score on a scale	MEAN
OTHER_PRE_SPECIFIED	Cardiovascular Effect	8 weeks	Due to technical problems with equipment, data were not captured for analysis.
OTHER_PRE_SPECIFIED	Volume of Diastolic Filling	8 weeks	Cardiovascular effects were not measured in the Rapamycin versus placebo group, only open label rapamycin group.	milliliters	MEAN

Source ClinicalTrials.gov

Results by group7

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Immunological Responses	Rapamycin	8.33	Standard Deviation 3.82	cells/mm^3
Immunological Responses	Placebo	11.24	Standard Deviation 4.45	cells/mm^3
Physical Performance	Rapamycin	7.75	Standard Deviation 1.12	Seconds
Physical Performance	Placebo	7.17	Standard Deviation 1.12	Seconds
Cognitive Function	Rapamycin	7.2	Standard Deviation 4.52	score on a scale
Cognitive Function	Placebo	6.92	Standard Deviation 4.23	score on a scale
Volume of Diastolic Filling	Rapamycin Alone - Cardiovascular Effects	132.84	Standard Deviation 26.82	milliliters

Source ClinicalTrials.gov

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Rapamycin	14
Overall Study	STARTED	Placebo	14
Overall Study	STARTED	Rapamycin Alone - Cardiovascular Effects	6
Overall Study	COMPLETED	Rapamycin	11
Overall Study	COMPLETED	Placebo	14
Overall Study	COMPLETED	Rapamycin Alone - Cardiovascular Effects	6
Overall Study	NOT COMPLETED	Rapamycin	3
Overall Study	NOT COMPLETED	Placebo	0
Overall Study	NOT COMPLETED	Rapamycin Alone - Cardiovascular Effects	0

Source ClinicalTrials.gov

Adverse events6

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Rash of face	General disorders	Rapamycin	1	14	1
other	Rash of face	General disorders	Placebo	0	14	0
other	Rash of face	General disorders	Rapamycin Alone - Cardiovascular Effects	0	6	0
other	Diarrhea	Gastrointestinal disorders	Rapamycin	1	14	1
other	Diarrhea	Gastrointestinal disorders	Placebo	0	14	0
other	Diarrhea	Gastrointestinal disorders	Rapamycin Alone - Cardiovascular Effects	0	6	0

Source ClinicalTrials.gov

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Rapamycin	0	14
Total, all-cause mortality	Placebo	0	14
Total, all-cause mortality	Rapamycin Alone - Cardiovascular Effects	0	6
Total, other adverse events	Rapamycin	2	14
Total, other adverse events	Placebo	0	14
Total, other adverse events	Rapamycin Alone - Cardiovascular Effects	0	6
Total, serious adverse events	Rapamycin	0	14
Total, serious adverse events	Placebo	0	14
Total, serious adverse events	Rapamycin Alone - Cardiovascular Effects	0	6

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests2

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

Test	Named as	Source
Design Fluency Test	Secondary outcome	ConductCognition
Verbal Fluency	Secondary outcome	ConductCognition

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02874924

GET https://conductscience.org/api/trials/v1/NCT02874924/registered

API reference For AI assistants